Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 512 of 5804
-
New vaccine aims to keep leukemia in remission
Disease control Recruiting nowAcute myeloid leukemia (AML) is the most common acute leukemia in adults. While approximately 70% of patients achieve complete remission (CR) with induction chemotherapy, traditional consolidation therapy (predominantly high-dose cytarabine) has a persistently high recurrence rat…
Phase: PHASE1 • Sponsor: Fujian Medical University Union Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New procedure aims to keep weight off after GLP-1 drugs are stopped
Disease control OngoingFractyl is evaluating Revita Duodenal Mucosal Resurfacing (DMR) in the REMAIN-1 pivotal study, which is designed to include two cohorts - an open label cohort referred to as REVEAL-1, and a randomized cohort, which includes both a midpoint analysis and a pivotal analysis. Patient…
Phase: NA • Sponsor: Fractyl Health Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Which blood thinner combo best prevents a second stroke?
Disease control Recruiting nowAlong with the current clinical trial, the efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of the first-ever large-vessel minor stroke or TIA compared to 300 mg clopidogrel were assessed through NIHSS, mRS, and possible adverse effects.
Phase: PHASE3 • Sponsor: Kafrelsheikh University • Aim: Disease control
Last updated Jun 26, 2026 13:49 UTC
-
Cholesterol drug may block melanoma spread in High-Risk patients
Prevention OngoingThis clinical trial tests whether atorvastatin prevents metastasis of resected high-risk stage IIA, IIB or IIIA melanoma. The vast majority of melanomas are diagnosed at an early, localized stage. However, approximately 10-15% of these localized melanomas will eventually metastas…
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Prevention
Last updated Jun 27, 2026 11:00 UTC
-
New hope for depression: quick switch to stronger meds may prevent chronic suffering
Symptom relief Recruiting nowOver 28 million people suffer from current depressive disorder in the European Union. Major depressive disorder (MDD) is one of the most common psychiatric illnesses. The symptoms cause clinically significant distress or impairment in social, occupational, and other important are…
Phase: PHASE3 • Sponsor: Dr. Inge Winter • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
New antibody combo takes on Hard-to-Treat stomach cancers
Disease control OngoingThis study will investigate the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) in combination with pembrolizumab in in microsatellite instability-high/Defective mismatch repair (MSI-H/dMMR) locally advanced unresectable or metastatic gastric /GEJ ad…
Phase: PHASE1, PHASE2 • Sponsor: Servier Bio-Innovation LLC • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Teens who attempted suicide get digital lifeline in new study
Knowledge-focused Recruiting nowOur study is designed to study the efficacy of an Electronic based psycho-social intervention targeting healthy coping and problem solving skills to mitigate suicidal behaviour. This would integrate existing systems and bridge the gap in accessibility to care for suicidal behavio…
Phase: NA • Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
New hope for lung cancer patients with a specific gene mutation
Disease control Recruiting nowThe researchers are doing this study to see if sotorasib is a safe and effective treatment for people with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation who have not received treatment for their cancer since it became advanced. (Participants have not recei…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New cocktail of drugs aims to shrink Hard-to-Treat throat cancer
Disease control Recruiting nowThe goal of this study is to learn the efficacy and safety of nimotuzumab combined with toripalimab and gemcitabine/cisplatin regimen treatment recurrent/distant-metastasis nasopharyngeal carcinoma.
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 26, 2026 19:08 UTC
-
New drug aims to protect kidneys in IgA nephropathy patients
Disease control OngoingThe purpose of this study is to evaluate the efficacy of povetacicept in adult participants compared with placebo in reducing proteinuria and preserving renal function.
Phase: PHASE3 • Sponsor: Alpine Immune Sciences Inc, A Subsidiary of Vertex • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Radioactive 'Smart Bomb' targets Hard-to-Treat prostate cancer in first human trial
Disease control Recruiting nowThe purpose of this study is to evaluate the safety, therapeutic effect, and pharmacokinetics of \[225Ac\]Ac-FL-020 in participants with metastatic castration-resistant prostate cancer (mCRPC).
Phase: PHASE1 • Sponsor: Full-Life Technologies UK Limited • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug combo aims to improve lymphoma treatment
Disease control OngoingThe purpose of this study is to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma (FL).
Phase: PHASE2 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New vacuum device aims to stop postpartum bleeding without surgery
Disease control OngoingThe purpose of this study is to evaluate the safety and effectiveness of the KOKO™ device in the control and reduction of primary abnormal postpartum uterine bleeding or hemorrhage.
Phase: NA • Sponsor: KOKO Medical Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug aims to stop dangerous gut infection from returning
Prevention Recruiting nowThis is a multisite study to evaluate the safety, tolerability, and efficacy of LMN-201 in participants recently diagnosed with CDI who are scheduled to receive or are receiving SOC antibiotic therapy against C. difficile.
Phase: PHASE2, PHASE3 • Sponsor: Lumen Bioscience, Inc. • Aim: Prevention
Last updated Jun 27, 2026 09:04 UTC
-
New heart valve implant offers hope for patients too sick for surgery
Disease control Recruiting nowProspective, multi-center study to assess safety and performance of the TRiCares Topaz Tricuspid Valve Replacement System
Phase: NA • Sponsor: TRiCares • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Sound waves zapping liver tumours without a scalpel
Disease control OngoingHistotripsy is a promising non-invasive technique that uses high-intensity ultrasound waves to disrupt tissue without damaging surrounding structures. It works by using high-intensity ultrasound waves to create microscopic bubbles within the tumour tissue. These bubbles rapidly e…
Phase: NA • Sponsor: The University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New bladder cancer drug shows promise in Late-Stage trial
Disease control OngoingThis Phase 3, single-arm, multicenter study will evaluate the efficacy and safety of UGN-103, a novel formulation of UGN-102, instilled in the urinary bladder of patients with low-grade non-muscle invasive bladder cancer (LG-NMIBC).
Phase: PHASE3 • Sponsor: UroGen Pharma Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Could a green tea compound prevent second heart attacks?
Disease control OngoingThe aim of this double-blind, randomized, placebo-controlled, multicenter study is to evaluate the pathogenetic effects of the dietary supplement "Tertinat" on a fundamental mechanism of atherosclerosis development: its ability to inhibit pathological desialylation of low-density…
Phase: PHASE2 • Sponsor: Institute for Atherosclerosis Research, Russia • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New triple therapy targets tough leukemia
Disease control Recruiting nowTo find a recommended combination dose of decitabine and venetoclax that can be given in combination with olutasidenib to participants with AML.
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New hope for endometrial cancer: targeted drug faces off against standard chemo
Disease control OngoingThe goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC). The…
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC